As for other microorganisms that infect humans, drug resistance has long been recognized in of medical importance, such as Candida and Aspergillus spp. Fungi tend to get less publicity than bacteria and viruses – perhaps because invasive (systemic) fungal infections are of most concern for special populations like hospitalized and immunocompromised people. However, a recent Dutch report documents the high of such infections.
Some features of fungi and of make them especially fascinating “One Health” examples of resistance, and potentially fruitful research topics. In particular, currently there are just a few classes of antifungal agents with just a few mechanisms of action, and – as highlighted in a recent – these are used across human and veterinary medicine, in agriculture for crop protection, and for other environmental purposes such as preservation of wooden structures. This widespread use encourages development and spread of antifungal resistance.
On the clinical front, a Lancet Infectious Diseases neatly summarized “[t]he global problem of antifungal resistance: prevalence, mechanisms, and management.” Antifungal (AFS) programmes are attracting attention, and a newly published on such an effort in a London hospital found that specialist guidance “to optimize antifungal prescribing resulted in significant cost savings without compromising on microbiological or clinical outcomes.” Quicker for fungi, and possibly of existing agents are the focus of current R&D.
If you enjoyed this article and would like to build a career in global health, we offer a range of MSc programmes covering health and data, infectious and tropical diseases, population health, and public health and policy.
Available on campus or online, including flexible study that works around your work and home life, be part of a global community at the UK's no.1 public health university.